Teladoc Health (NYSE:TDOC) Shares Gap Up – Time to Buy?

Teladoc Health, Inc. (NYSE:TDOC) shares gapped up before the market opened on Thursday . The stock had previously closed at $6.59, but opened at $6.97. Teladoc Health shares last traded at $6.9880, with a volume of 870,828 shares traded.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc announced that its virtual care services are now available through Walmart’s Better Care Services platform, giving the company access to Walmart’s large customer base and potentially expanding adoption of services like virtual urgent care, dermatology, and nutrition. Article Title
• Positive Sentiment: Investors also reacted favorably to coverage noting that the Walmart deal broadens Teladoc’s distribution, with BofA describing the move as a modest positive for the stock. Article Title
• Positive Sentiment: Shares have also been supported by momentum after the latest earnings report, with the stock up sharply since results were released and analysts watching whether the post-earnings strength can continue. Article Title
• Neutral Sentiment: Recent roundup coverage on Q1 results did not add a major new catalyst, but it kept attention on how Teladoc is performing relative to peers in the online marketplace and healthcare services space. Article Title
• Neutral Sentiment: Jefferies raised its price target on Teladoc, but kept a Hold rating, signaling some improved outlook without a full bullish conviction. Article Title

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TDOC. Deutsche Bank Aktiengesellschaft raised Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Tuesday, March 10th. Barclays decreased their price target on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Oppenheimer decreased their price target on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 3rd. TD Cowen decreased their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Finally, Stifel Nicolaus decreased their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.43.

Teladoc Health Price Performance

The business has a 50-day simple moving average of $6.01 and a 200 day simple moving average of $6.22. The firm has a market cap of $1.37 billion, a P/E ratio of -7.85 and a beta of 2.08. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The business had revenue of $613.85 million for the quarter, compared to the consensus estimate of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, analysts anticipate that Teladoc Health, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the transaction, the chief executive officer owned 364,784 shares of the company’s stock, valued at $2,002,664.16. This represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.70% of the stock is owned by insiders.

Institutional Trading of Teladoc Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Teladoc Health by 4.2% in the third quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after buying an additional 891,732 shares during the period. Renaissance Technologies LLC lifted its holdings in Teladoc Health by 1.3% in the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock worth $44,066,000 after buying an additional 107,400 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Teladoc Health by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock worth $52,459,000 after buying an additional 605,061 shares during the period. Geode Capital Management LLC lifted its holdings in Teladoc Health by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock worth $29,324,000 after buying an additional 18,394 shares during the period. Finally, Jupiter Asset Management Ltd. lifted its holdings in Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after buying an additional 2,880,008 shares during the period. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.